Market
What percentage of the 2 million target will be reached with Lenacapavir by end of 2025?
2
Resolution / Starting Odds
Less than 50% • 25%
50% to 75% • 25%
76% to 99% • 25%
100% or more • 25%
Reports from Gilead Sciences or Global Fund/PEPFAR updates
Story
Gilead's Lenacapavir Named 2024 Breakthrough for HIV Prevention, Aiming to Reach 2 Million
Dec 17, 2024, 08:38 AM
Lenacapavir, a new injectable drug developed by Gilead Sciences, has been named the 2024 Breakthrough of the Year by the scientific journal Science. Administered every six months, the drug has demonstrated remarkable success in preventing HIV infection, with clinical trials showing 100% effectiveness in preventing HIV among women in Africa and 99.9% effectiveness among diverse gender groups globally. Lenacapavir targets the HIV capsid, a protein that protects the virus's genetic material, and its mechanism could potentially influence treatments for other viral diseases. The Global Fund to Fight AIDS, Tuberculosis and Malaria, along with the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), have announced a coordinated effort to provide affordable access to lenacapavir for HIV pre-exposure prophylaxis (PrEP) to at least 2 million people over three years in countries they support, contingent upon regulatory approvals from the U.S. Food and Drug Administration, national pharmaceutical regulators, and a recommendation from the World Health Organization (WHO).
View original story
Similar markets
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Reduction by more than 15% • 25%
Reduction by less than 5% • 25%
Reduction by 5% to 10% • 25%
Reduction by 10% to 15% • 25%
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
5-9 countries • 25%
10-14 countries • 25%
1-4 countries • 25%
15 or more countries • 25%
Adolescents • 25%
Pregnant women • 25%
Elderly • 25%
Adults • 25%
Europe • 25%
North America • 25%
Asia • 25%
Africa • 25%
Approved in USA only • 25%
Not approved in USA or EU • 25%
Approved in both USA and EU • 25%
Approved in EU only • 25%